DOP2010000199A - Derivados de 19-nor-esteroide que tiene, un grupo 15a, 16a-metileno y un anillo de 17,17- espirolactona saturado, su uso y medicamentos que los comprenden - Google Patents

Derivados de 19-nor-esteroide que tiene, un grupo 15a, 16a-metileno y un anillo de 17,17- espirolactona saturado, su uso y medicamentos que los comprenden

Info

Publication number
DOP2010000199A
DOP2010000199A DO2010000199A DO2010000199A DOP2010000199A DO P2010000199 A DOP2010000199 A DO P2010000199A DO 2010000199 A DO2010000199 A DO 2010000199A DO 2010000199 A DO2010000199 A DO 2010000199A DO P2010000199 A DOP2010000199 A DO P2010000199A
Authority
DO
Dominican Republic
Prior art keywords
hydrogen
methylene
group
derivatives
alkyl
Prior art date
Application number
DO2010000199A
Other languages
English (en)
Inventor
Hans-Peter Muhn
Ulrich Klar
Rolf Bohlmann
Katja Prelle
Steffen Borden
Frederik Menges
Joachim Kuhnke
Jan Hubner
Sven Ring
Thomas Frenzel
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40548690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2010000199(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of DOP2010000199A publication Critical patent/DOP2010000199A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001—Lactones
    • C07J21/003—Lactones at position 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Los derivados de y-lactona del ácido 15a,l6ct-metilen- 17-hidroxi-19-nor-17-pregna-4-en-3-ona-21-carboxílico de la presente invención poseen efectividad gestagénica. Tienen la fórmula química general I, en la cual Z se selecciona del grupo que comprende un átomo de oxígeno, dos átomos de hidrógeno, NOR y NNHSO2R, donde R es hidrógeno, alquilo-C1- c1o, arilo o aralquilo-C7-c20, R4 es hidrógeno o halógeno; además, R6a, R6b forman juntos metileno o 1,2-etandiilo o R6a es hidrógeno y R6b se selecciona del grupo que comprende hidrógeno, alquilo-C1-C10, alquenilo-C2-C10 o alquinilo-C2- C10, y R7 se selecciona del grupo que comprende hidrógeno, alquilo-C1-C10, cicloalquilo-C3-C6, alquenilo-C2-C10 o alquinilo-C2-c10, o: R6a es hidrógeno y R6b y R7 juntos forman un enlace, un oxígeno o metileno, R8 representa hidrógeno o a1qui1o-C-C3 y comprenden además sus solvatos, hidratos, estereoisómeros y sales.
DO2010000199A 2007-12-29 2010-06-29 Derivados de 19-nor-esteroide que tiene, un grupo 15a, 16a-metileno y un anillo de 17,17- espirolactona saturado, su uso y medicamentos que los comprenden DOP2010000199A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007063495A DE102007063495A1 (de) 2007-12-29 2007-12-29 19-Nor-Steroidderivate mit einer 15α,16α-Methylengruppe und einem gesättigten 17,17-Spirolactonring, deren Verwendung sowie diese Derivate enthaltende Arzneimittel

Publications (1)

Publication Number Publication Date
DOP2010000199A true DOP2010000199A (es) 2010-10-15

Family

ID=40548690

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2010000199A DOP2010000199A (es) 2007-12-29 2010-06-29 Derivados de 19-nor-esteroide que tiene, un grupo 15a, 16a-metileno y un anillo de 17,17- espirolactona saturado, su uso y medicamentos que los comprenden

Country Status (26)

Country Link
US (2) US20100311702A1 (es)
EP (1) EP2238149B1 (es)
JP (1) JP5600071B2 (es)
KR (1) KR20100102136A (es)
CN (1) CN101910192B (es)
AR (1) AR069962A1 (es)
AU (1) AU2008342916A1 (es)
BR (1) BRPI0821666A2 (es)
CA (1) CA2710495C (es)
CL (1) CL2008003919A1 (es)
CO (1) CO6290675A2 (es)
DE (1) DE102007063495A1 (es)
DO (1) DOP2010000199A (es)
EA (1) EA201000982A1 (es)
EC (1) ECSP10010315A (es)
ES (1) ES2539121T3 (es)
HK (1) HK1151532A1 (es)
IL (1) IL206019A0 (es)
NZ (1) NZ586453A (es)
PA (1) PA8810701A1 (es)
PE (1) PE20091336A1 (es)
TW (1) TW200940074A (es)
UA (1) UA98834C2 (es)
UY (1) UY31580A1 (es)
WO (1) WO2009083272A2 (es)
ZA (1) ZA201005395B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8334375B2 (en) * 2009-04-10 2012-12-18 Evestra, Inc. Methods for the preparation of drospirenone
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
TW201350122A (zh) * 2012-04-23 2013-12-16 Bayer Pharma AG １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1183500B (de) 1962-10-12 1964-12-17 Schering Ag Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe
US3705179A (en) 1971-03-15 1972-12-05 American Home Prod Antiandrogenic steroids
US4188951A (en) * 1972-08-17 1980-02-19 Alza Corporation Intrauterine system embracing selected copolymeric membranes for administering beneficial agent
NL7701384A (nl) 1977-02-10 1978-08-14 Akzo Nv Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks.
DE2922500A1 (de) 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
DE3402329A1 (de) 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE19651000A1 (de) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
DE102004063864A1 (de) * 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
US8445469B2 (en) * 2004-12-30 2013-05-21 Bayer Intellectual Property Gmbh 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter
WO2009111574A2 (en) * 2008-03-05 2009-09-11 Evestra, Inc. BISMETHYLENE-17α CARBOLACTONES AND RELATED USES

Also Published As

Publication number Publication date
WO2009083272A2 (de) 2009-07-09
AR069962A1 (es) 2010-03-03
EA201000982A1 (ru) 2011-02-28
PE20091336A1 (es) 2009-10-04
EP2238149A2 (de) 2010-10-13
CA2710495C (en) 2015-04-28
AU2008342916A1 (en) 2009-07-09
JP5600071B2 (ja) 2014-10-01
DE102007063495A1 (de) 2009-09-17
JP2011507928A (ja) 2011-03-10
ES2539121T3 (es) 2015-06-26
TW200940074A (en) 2009-10-01
ECSP10010315A (es) 2010-08-31
NZ586453A (en) 2012-05-25
EP2238149B1 (de) 2015-03-18
US20100311702A1 (en) 2010-12-09
CO6290675A2 (es) 2011-06-20
US20130123219A1 (en) 2013-05-16
CA2710495A1 (en) 2009-07-09
ZA201005395B (en) 2012-01-25
IL206019A0 (en) 2010-11-30
CN101910192B (zh) 2013-07-31
UY31580A1 (es) 2009-08-03
UA98834C2 (ru) 2012-06-25
CL2008003919A1 (es) 2010-05-07
US8987239B2 (en) 2015-03-24
HK1151532A1 (es) 2012-02-03
BRPI0821666A2 (pt) 2015-06-16
WO2009083272A3 (de) 2009-08-27
CN101910192A (zh) 2010-12-08
KR20100102136A (ko) 2010-09-20
PA8810701A1 (es) 2009-12-16

Similar Documents

Publication Publication Date Title
AR107519A1 (es) Compuestos de piperidina sustituido y su uso
PA8784201A1 (es) Derivado de 17b-ciano-18a-homo-19-nor-androst-4-eno, su uso y medicamento que lo contiene
ECSP099335A (es) Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos
CU20100157A7 (es) Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CO6321168A2 (es) Nuevos derivados de 2-amidotiadiazol
CO2018010787A2 (es) Compuesto de griseofulvina
CY1124908T1 (el) Παραγωγο μορφινανης
AR090112A1 (es) Sulfinilaminobenzamidas efectivas como herbicidas
DOP2010000199A (es) Derivados de 19-nor-esteroide que tiene, un grupo 15a, 16a-metileno y un anillo de 17,17- espirolactona saturado, su uso y medicamentos que los comprenden
PA8784401A1 (es) Derivado de 17b-ciano-19-nor-androst-4-eno, su uso y medicamento que lo contiene
AR077429A1 (es) Compuestos hidroxiasenapina sus derivados y composiciones farmaceuticas que comprenden los mismos
CY1114378T1 (el) Μεθοδος χρησιμοποιησης συνδυασμου παραγωγου βενζοφαινονης ή αλατος αυτου και ανοσοκατασταλτικου παραγοντα, και φαρμακευτικη συνθεση που περιλαμβανει αυτα τα συστατικα
CU20100137A7 (es) Derivados de 19-nor-esteroide que tiene un grupo 15, 16-metileno y un anillo de 17, 17-espirolactona saturado, su uso y medicamentos que los comprenden
BR112015023280A2 (pt) derivados de dihidroquinolin-2-ona para utilização como inibidores da aldosterona sintase
BRPI0912266B8 (pt) composto derivado de óxido de benzotiofeno, e, composição farmacêutica
AR069963A1 (es) Derivado 15, 16-metilen-17- (1'-propenil)-17-3'-oxidoestra-4-en-3-ona, su uso y medicamento que lo contiene
ECSP12011711A (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR069965A1 (es) Derivado de (gamma)-lactona de esteroide de acido 15, 16 -metilen-17-hidroxi-19-nor-21-carboxilico, su uso para preparar un medicamento que lo contiene y medicamento que contiene al compuesto
NI201300028A (es) Nuevos derivados dihidrobenzoxatiazepinas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
UY31582A1 (es) Derivado de 17- ( 1' - propenil) - 17-3' - oxidoestra-4-en-3-ona, su uso y medicamentos que lo contienen
TH91788B (th) อนุพันธ์เบนซิมิดาโซลและเบนโซไธอะโซลใหม่, กรรมวิธีการเตรียมสำหรับสารนั้น, การใช้สารนั้นเป็นยา, องค์ประกอบทางเภสัชกรรมและการใช้แบบใหม่โดยเฉพาะอย่างยิ่งเป็นสารยับยั้ง cmet
TH91788A (th) อนุพันธ์เบนซิมิดาโซลและเบนโซไธอะโซลใหม่, กรรมวิธีการเตรียมสำหรับสารนั้น, การใช้สารนั้นเป็นยา, องค์ประกอบทางเภสัชกรรมและการใช้แบบใหม่โดยเฉพาะอย่างยิ่งเป็นสารยับยั้ง cmet
TH168483A (th) อนุพันธ์ของอิมิแดโซ-ไทรแอซีน เป็นตัวยับยั้ง pde10
TH1701005400A (th) อนุพันธ์ไบไซคลิกเฮเทอโรเอริลแบบเชื่อม
CU20100139A7 (es) Derivados de y-lactona de esteroide de ácido 15,16-metilen-17-hidroxi-19-nor-21-carboxílico, su uso y medicamentos que contienen tal derivado